Nuacht

GlobalData on MSN9 uair an chloig
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
The Munich Eye2 uair an chloig
FDA Grants Approval for Dupixent to Treat Bullous Pemphigoid
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)
Regeneron's Dupixent leads growth as Eylea sales decline. Oncology focus grows. Valuation attractive, but growth delayed by 2 ...
PMLive2 lá
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...
FDA approves Dupixent for bullous pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Medical Dialogues3 lá
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
MPR1 lá
Dupixent Gains Approval for Bullous Pemphigoid
The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Medical Dialogues5 lá
Sanofi Dupixent gets USFDA nod for bullous pemphigoid treatment in adults
Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...
pharmaphorum5 lá
Dupixent is first FDA-approved drug for rare skin disease
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...